Vaxcyte Inc. S.
Furthermore, the candidate met noninferiority benchmarks for nine serotypes shared exclusively with PCV20 and eight serotypes shared solely with PCV21. Strong Immunobridging And Safety ProfileThe trial also evaluated immunobridging in adults aged 18 to 49 compared to adults aged 50 to 64.
62 during premarket trading on Monday. The stock is trading at a new 52-week high, according to Benzinga Pro data.
